[go: up one dir, main page]

CL2007001894A1 - Topical ophthalmic formulation comprising: 0.1% dexamethasone, 0.3% ciprofloxacin hydrochloride, sodium chloride, 6% hydroxypropyl beta-cyclodextrin, 0.15% sodium sulfate, 0.05% edetate disodium, 0.022% 50% benzalkonium chloride and 0.100ml / 100ml polysorbate 80; Useful for treating eye infections. - Google Patents

Topical ophthalmic formulation comprising: 0.1% dexamethasone, 0.3% ciprofloxacin hydrochloride, sodium chloride, 6% hydroxypropyl beta-cyclodextrin, 0.15% sodium sulfate, 0.05% edetate disodium, 0.022% 50% benzalkonium chloride and 0.100ml / 100ml polysorbate 80; Useful for treating eye infections.

Info

Publication number
CL2007001894A1
CL2007001894A1 CL2007001894A CL2007001894A CL2007001894A1 CL 2007001894 A1 CL2007001894 A1 CL 2007001894A1 CL 2007001894 A CL2007001894 A CL 2007001894A CL 2007001894 A CL2007001894 A CL 2007001894A CL 2007001894 A1 CL2007001894 A1 CL 2007001894A1
Authority
CL
Chile
Prior art keywords
dexamethasone
polysorbate
chloride
cyclodextrin
useful
Prior art date
Application number
CL2007001894A
Other languages
Spanish (es)
Inventor
De Dios Quintana Hau Juan
Ruben Tornero Montano Jose
Martin Baiza Duran Leopoldo
Patricia Rodriguez Franco Norma
R Jaime
Original Assignee
Arturo Jimenez Bayardo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38845821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007001894(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arturo Jimenez Bayardo filed Critical Arturo Jimenez Bayardo
Publication of CL2007001894A1 publication Critical patent/CL2007001894A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formulación oftálmica para administración vía tópica que comprende dexametasona base micronizada, clorhidrato de ciprofloxacino, cloruro de sodio, hidroxipropilbetaciclodextrinas, sulfato de sodio, edetato disódico, cloruro de benzalconio y polisorbato 80.Ophthalmic formulation for topical administration comprising dexamethasone micronized base, ciprofloxacin hydrochloride, sodium chloride, hydroxypropylbetacyclodextrins, sodium sulfate, disodium edetate, benzalkonium chloride and polysorbate 80.

CL2007001894A 2006-06-27 2007-06-27 Topical ophthalmic formulation comprising: 0.1% dexamethasone, 0.3% ciprofloxacin hydrochloride, sodium chloride, 6% hydroxypropyl beta-cyclodextrin, 0.15% sodium sulfate, 0.05% edetate disodium, 0.022% 50% benzalkonium chloride and 0.100ml / 100ml polysorbate 80; Useful for treating eye infections. CL2007001894A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2006/000062 WO2008002117A1 (en) 2006-06-27 2006-06-27 Ophthalmic solution of ciprofloxacin and dexamethasone

Publications (1)

Publication Number Publication Date
CL2007001894A1 true CL2007001894A1 (en) 2008-01-04

Family

ID=38845821

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2007001894A CL2007001894A1 (en) 2006-06-27 2007-06-27 Topical ophthalmic formulation comprising: 0.1% dexamethasone, 0.3% ciprofloxacin hydrochloride, sodium chloride, 6% hydroxypropyl beta-cyclodextrin, 0.15% sodium sulfate, 0.05% edetate disodium, 0.022% 50% benzalkonium chloride and 0.100ml / 100ml polysorbate 80; Useful for treating eye infections.

Country Status (3)

Country Link
CL (1) CL2007001894A1 (en)
PE (1) PE20080347A1 (en)
WO (1) WO2008002117A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107970244B (en) * 2016-10-21 2020-07-14 武汉武药科技有限公司 Composition containing ciprofloxacin and dexamethasone and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6740664B2 (en) * 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
US20040077562A1 (en) * 2000-11-15 2004-04-22 Chandavarkar Mohan A. Combination drug
WO2004069280A1 (en) * 2003-02-06 2004-08-19 Cipla Ltd Pharmaceutical inclusion complexes containing a steroid and optionally an antibacterial agent
MXPA05008913A (en) * 2003-02-21 2005-10-05 Sun Pharmaceutical Ind Ltd Stable ophthalmic formulation containing an antibiotic and a corticosteroid.

Also Published As

Publication number Publication date
WO2008002117A1 (en) 2008-01-03
PE20080347A1 (en) 2008-04-11

Similar Documents

Publication Publication Date Title
CY1108676T1 (en) Ophthalmic suspension comprising an ophthalmic drug, a poloxamine AND AN AGENT REGULATION OF TONIKOTITAS TYPE GLYKOLIS, USE OF SAID COMPOSITION FOR THE PRODUCTION OF A medicament for treating ophthalmic disorders
ATE535257T1 (en) OPHTHALMOLOGICAL FORMULATION WITH METHYLSULFONYLMETHANE AND CIPROFLOXACIN
BRPI0509863A (en) drug release to the eye fundus
BR0317572A (en) Benzoxazine and its derivatives as inhibitors of pi3ks
ZA200709188B (en) Pharmaceutical compositions of a neuroactive steroid and uses thereof
PT2038290E (en) Modulators of toll-like receptor 7
ATE496623T1 (en) OXCARBAZEPINE CONTROLLED RELEASE PREPARATIONS WITH SIGMOIDAL RELEASE PROFILE
BRPI0615860B8 (en) solid monolithic extended release pharmaceutical composition
BRPI0417820A (en) azabicyclic heterocycles as cannabinoid receptor modulators
BRPI0417771A (en) azabicyclic heterocycles as cannabinoid receptor modulators
AR067011A1 (en) FORMULATIONS OF ANTIBODIES
BRPI0509184A (en) pharmaceutical compositions
BRPI0411017A (en) 3-substituted indoles and derivatives thereof as therapeutic agents
MX2010005013A (en) Intranasal compositions.
TW200626132A (en) Topical nepafenac formulations
EA200901393A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING GESTAGENES AND / OR ESTROGENS AND 5 METHYL- (6S) -TETRAHYDROPHOLATE
CY1112269T1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT, REDUCTION, IMPROVEMENT, OR REDUCTION OF RED-SECTION EYE DISEASES
PH12019500328A1 (en) Aza-indazole compounds for use in tendon and/or ligament injuries
BRPI0511923A (en) stabilized compositions comprising a citric acid therapeutically active agent or a conjugate base and chlorine dioxide
CL2007001894A1 (en) Topical ophthalmic formulation comprising: 0.1% dexamethasone, 0.3% ciprofloxacin hydrochloride, sodium chloride, 6% hydroxypropyl beta-cyclodextrin, 0.15% sodium sulfate, 0.05% edetate disodium, 0.022% 50% benzalkonium chloride and 0.100ml / 100ml polysorbate 80; Useful for treating eye infections.
ES2188563T3 (en) STABLE SOLUTION OF XYLOMETAZOLINE AND OXIMETAZOLINE.
JOP20190054B1 (en) Indazole compounds for use in tendon and/or ligament injuries
TW201542242A (en) Ophthalmic composition for negative ion soft contact lenses
AR074828A1 (en) COMPOSITIONS OF TOPIC EYE SOLUTIONS TO MANAGE EFFECTIVE CONCENTRATIONS OF AN ACTIVE AGENT TO THE BACK EYE SEGMENT
BRPI0510906A (en) topical pharmaceutical composition, topical administration composition and its use